Last updated: July 25, 2026
IOPAMIDOL-250 (iodinated, non-ionic X-ray contrast media; 250 mg I/mL) is a long-established product used in CT and angiography. There is no single dominant, current global “trial pipeline” public signal for the specific strength/labeling “IOPAMIDOL-250” that can be mapped to a discrete, near-term clinical-lead asset. Commercial outlook is therefore dominated by (1) generics and authorized equivalents, (2) reimbursement and procurement patterns in radiology, (3) imaging utilization trends (CT volumes), and (4) supply-chain and regulatory continuity risk across iodinated contrast manufacturers.
Are there active clinical trials for iopamidol-250 in 2025?
Featured snippet: Public trial visibility for “IOPAMIDOL-250” specifically is limited; most registries track iopamidol broadly (often multiple strengths), not the 250 mg I/mL presentation as a stand-alone development target.
What do public registries typically show for iopamidol studies?
Clinical activity for iopamidol historically clusters around:
- Comparative imaging performance in CT protocols (contrast timing, arterial vs venous phases).
- Safety and tolerability in higher-risk subgroups (renal impairment considerations, hydration protocols, hypersensitivity observation).
- Intravascular vs intraluminal administration comparisons (angiography and interventional radiology workflows).
- Device or protocol studies (injection rates, power injectors, bolus geometry) that often use iopamidol variants.
Why “iopamidol-250” trial granularity is usually low
For established contrast agents, development often occurs as:
- Bioequivalence/CMC support for generic/authorized versions rather than novel phase 2/3 clinical endpoints.
- Label updates driven by post-marketing commitments, pharmacovigilance analyses, or risk management.
Net effect for planning: Expect a slower cadence of new efficacy trials tied to iopamidol itself. The “clinical trials update” in 2025 is more likely to be protocol and safety research than new indication claims that materially change market value for a single strength.
How large is the iodinated contrast market and where does iopamidol-250 fit?
Featured snippet: iopamidol is a category member in iodinated contrast media (ICM), a high-volume procurement class driven by CT and interventional procedures.
Iodinated contrast media demand drivers
- Rising CT utilization per capita and increasing outpatient imaging share.
- Interventional radiology growth (angiography-adjacent workflows).
- Ageing populations increasing imaging frequency and comorbidity-related scanning.
Iopamidol’s role in contrast procurement
Procurement tends to prioritize:
- Contract pricing and tendering across hospital systems.
- Availability and supply reliability across dosing sizes.
- Perceived safety profile and established clinical familiarity among radiologists.
Strategic inference: For iopamidol-250, unit economics follow tender dynamics more than breakthrough innovation. The main “market edge” comes from pricing, supply, and formulary placement.
What is the competitive landscape for iopamidol (250 mg I/mL) in CT?
Featured snippet: Competition is dominated by other non-ionic iodinated monomers and multiple iopamidol generics/authorized copies rather than novel branded entrants.
Key competitor clusters (by procurement logic)
- Other non-ionic, low-osmolality iodinated monomers (used interchangeably in many CT protocols).
- Authorized generics and branded generics of iopamidol across equivalent strengths.
- Regional supply players with strong hospital network penetration.
Where iopamidol-250 competes most directly
- Hospitals with established contrast bundles selecting a limited set of contract-preferred agents.
- Emergency and high-throughput imaging centers needing stable supply.
- Interventional centers using rapid injection protocols where formulation consistency matters.
When does iopamidol face generic competition risk, and what does it mean for iopamidol-250 pricing?
Featured snippet: Generic pressure typically stabilizes or compresses pricing; differentiation shifts to availability, vial/bag formats, and tender compliance.
Generic entry mechanics that matter for pricing
For an established contrast agent, pricing impact generally comes from:
- Launch of authorized equivalents or generic versions of iopamidol at the same concentration and common package sizes.
- Expansion of tender networks that move volume from higher-cost SKUs to lower-cost equivalents.
- Substitution rules in formularies and contrast preference protocols.
What to expect in 2025-2030 pricing behavior
- Periodic tender-driven price resets rather than continuous brand-specific declines.
- Margin compression for higher-cost distributors.
- Promotional or rebate strategies concentrated around contract renewals.
What regulatory and Orange Book status affects iopamidol-250?
Featured snippet: iopamidol is typically positioned as an established drug with FDA documentation that governs equivalence and labeling; detailed Orange Book exclusivity and patent maps depend on the specific NDA/ANDA and strength/packaging listings.
Practical regulatory implications
For contrast media, regulatory focus usually remains on:
- Manufacturing consistency and sterility assurance.
- Particulate matter and stability specifications for clinical-grade injectables.
- Labeling for indications, dosing, and warnings (hypersensitivity, renal impairment precautions).
Planning impact: Regulatory continuity tends to be a barrier to new entrants rather than a barrier to substitution once an approved equivalent exists.
How should you interpret “clinical trial update” for iopamidol-250 vs pure pipeline drugs?
Featured snippet: For iopamidol-250, clinical updates are more likely to be safety, protocol optimization, and operational practice than new efficacy breakthroughs.
Which trial types can move market share
Market-share impact tends to require one of the following:
- Evidence that a specific protocol reduces adverse events or improves workflow efficiency sufficiently to influence standard-of-care.
- Label expansions or clarified risk stratification that reduces physician reluctance.
- Comparative studies that lead procurement committees to prefer one agent over another in defined patient risk tiers.
IOPAMIDOL-250-specific expectation: Most incremental studies do not create a defensible IP moat. Without formulation innovation protected by strong patents, outcomes rarely translate into sustained premium pricing.
Market projection for iopamidol-250: What growth rate is realistic through 2030?
Featured snippet: Growth is expected to track imaging procedure volume and regional tender stabilization, with limited upside beyond demand growth and market-share shifts from contract dynamics.
Projection logic (contrast media)
For an established, substitutable contrast agent:
- Volume growth follows CT utilization growth and interventional procedure volume.
- Value growth is constrained by generics and tender-led price competition.
- Share shifts depend on reliability and procurement preference, not clinical differentiation.
Base-case outcomes to model
A realistic projection for iopamidol-250 typically shows:
- Moderate unit growth, reflecting procedure volume.
- Flat-to-low single digit net revenue growth in mature markets due to price pressure.
- More pronounced growth in regions where modern imaging adoption is accelerating and procurement is migrating from less reliable supply chains to contract-standardized products.
Which geographies are likely to offer the strongest iopamidol-250 demand?
Featured snippet: Demand strength typically concentrates where CT volumes expand and hospital networks consolidate purchasing.
Typical regional drivers
- Higher growth in emerging markets as imaging infrastructure expands.
- Demand resilience in North America and Western Europe tied to established imaging frequency and interventional radiology throughput.
- Tender centralization in large hospital groups influences annual contract renewals.
Operational implication: Success in new geographies usually depends on supply reliability, regulatory dossier readiness, and the ability to win recurring tender cycles.
Manufacturing and supply chain risks: What can disrupt iopamidol-250 availability?
Featured snippet: Iodinated contrast supply disruptions often originate from manufacturing capacity constraints, raw material availability, sterility assurance failures, or regulatory compliance actions.
Risk factors that matter for procurement planning
- Batch-to-batch consistency in particulate controls and stability.
- Capacity utilization at API and drug product facilities.
- Regulatory inspections and remediation timelines.
- Packaging constraints, including vial/bottle availability and labeling language compliance.
Market consequence: If supply tightens, price may temporarily rise, and formularies may be forced to substitute among available agents, shifting near-term market share.
What formulation or dosing changes could change the market for iopamidol-250?
Featured snippet: Future differentiation for iopamidol-250 likely comes from packaging format and delivery-system compatibility rather than new active ingredients.
Areas that can influence adoption
- Power-injector compatibility and injection-rate validation in labeling.
- Alternative container sizes aligned to procedural patterns (e.g., high-throughput CT vs angiography).
- Bulk supply agreements for health systems that reduce unit handling.
Investment lens: These improvements generally do not create long-duration exclusivity unless paired with enforceable IP around manufacturing method or specialized delivery formats.
How does iopamidol-250 compare with other non-ionic iodinated contrast media?
Featured snippet: Most non-ionic iodinated monomers are clinically interchangeable for many CT indications, so differences primarily affect procurement decisions, supply reliability, and local guideline preferences.
Comparison axes used by clinicians and procurement committees
- Tolerability and patient risk management practices (consistent across non-ionic monomers).
- Viscosity and injection performance at typical rates.
- Supply continuity and lead times.
- Contract pricing and formulary positioning.
Commercial implication: Unless a competitor wins a specific tender cycle, the “winner” is often the lowest landed cost with reliable availability.
Key Takeaways
- IOPAMIDOL-250 is a high-volume, established contrast media asset where clinical differentiation is limited and market performance is driven by procurement and imaging utilization.
- “Clinical trials update” for iopamidol is more likely to reflect protocol optimization and safety practice than new indication-granting breakthroughs.
- Market outlook through 2030 should be modeled with moderate unit growth tied to CT/interventional volume and constrained value growth from generics and tender price resets.
- Competitive dynamics are largely substitution-based within non-ionic iodinated monomers; iopamidol-250 share changes tend to follow contract wins and supply reliability.
- The highest business risk is not scientific failure but supply/regulatory continuity shocks that disrupt tender cycles.
FAQs
- What are the most common CT protocol considerations when using iopamidol-250 vs other non-ionic iodinated contrasts?
- How do hospital tender cycles typically shift market share for iopamidol-250 in the US and EU?
- What adverse event risk categories are most frequently monitored for iodinated contrast agents like iopamidol?
- Do injection rate and patient hydration protocols materially affect outcomes for iopamidol-250 use?
- What supply chain bottlenecks most often impact iodinated contrast availability and pricing?
References
- FDA. Drugs@FDA. U.S. Food and Drug Administration database (accessed 2026-07-25).
- DailyMed. iopamidol product labeling (accessed 2026-07-25).
- ClinicalTrials.gov. Search results for iopamidol studies (accessed 2026-07-25).
- American College of Radiology (ACR). Manual on Contrast Media (latest edition accessed 2026-07-25).
